US Patent Reform Would Raise Drug Costs
By weakening ways to challenge drug patent thickets, proposed legislation to reform US patent law would extend brand monopolies and increase spending on medicines, the Association for Accessible Medicines is warning.
You may also be interested in...
Genentech has been denied its request for a US injunction against Amgen over its at-risk launch of a trastuzumab biosimilar rival to Herceptin.
Mylan has succeeded in convincing the PTAB to invalidate two of Sanofi’s US formulation patents for its Lantus (insulin glargine) diabetes treatment.
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.